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ABSTRACT Cyclic nucleotide phosphodiesterases (PDEs) constitute a large superfamily of enzymes regulating concentra-
tions of intracellular second messengers cAMP and cGMP through PDE-catalyzed hydrolysis. Although three-dimensional x-ray
crystal structures of PDE4 and PDE5 have been reported, it is uncertain whether a critical, second bridging ligand (BL2) in the
active site is H2O or HO
 because hydrogen atoms cannot be determined by x-ray diffraction. The identity of BL2 is theoretically
determined by performing molecular dynamics simulations and hybrid quantum mechanical/molecular mechanical (QM/MM)
calculations, for the ﬁrst time, on the protein structures resolved by x-ray diffraction. The computational results conﬁrm our
previous suggestion, which was based on QM calculations on a simpliﬁed active site model, that BL2 in PDE4 should be HO,
rather than H2O, serving as the nucleophile to initialize the catalytic hydrolysis of cAMP. The molecular dynamics simulations
and QM/MM calculations on PDE5 demonstrate for the ﬁrst time that the BL2 in PDE5 should also be HO rather than H2O as
proposed in recently published reports on the x-ray crystal structures, which serves as the nucleophile to initialize the PDE5-
catalyzed hydrolysis of cGMP. These fundamental structural insights provide a rational basis for future structure-based drug
design targeting PDEs.
INTRODUCTION
Cyclic nucleotide phosphodiesterases (PDEs) constitute a
large superfamily (with at least 11 different gene families,
i.e., PDE1 to PDE11) of structurally related, functionally dis-
tinct, and highly regulated enzymes (1). Most PDE families
comprise more than one gene (;20 PDE genes), which
generate multiple protein products (.50 PDE proteins) via
alternative mRNA splicing or use of different promoters/
transcription initiation sites (2). PDEs regulate physiological
processes by degrading intracellular second messengers,
cyclic adenosine 39,59-monophosphate (cAMP) and cyclic
guanosine 39,59-monophosphate (cGMP), through PDE-
catalyzed hydrolysis (3–12). PDE4, PDE7, and PDE8 are
highly speciﬁc for cAMP, whereas PDE5, PDE6, and PDE9
are highly speciﬁc for cGMP. PDE1, PDE2, PDE3, PDE10,
and PDE11 exhibit dual speciﬁcity with greater or lesser
preference for cAMP or cGMP (3). Thus, PDEs are clinical
targets for such biological disorders as retinal degeneration,
congestive heart failure, depression, asthma, erectile dys-
function, and inﬂammation (5,13–18).
Selective inhibitors of PDEs have already been shown or
are expected to exert beneﬁcial effects in a number of
therapeutic areas, including stimulation of myocardial con-
tractility, inhibition of mediator release, inhibition of platelet
aggregation, cancer chemotherapy, analgesia, and treatment
of depression, Parkinson’s disease, and learning and memory
disorders (14,16,19–41). For example, selective inhibitors of
PDE4 may be used as new antidepressants, memory-enhancing
drugs, and novel antiasthmatic and antiinﬂammatory agents
for the treatment of chronic obstructive pulmonary disease
(COPD), asthma, and other respiratory diseases (42). Selective
inhibitors of PDE5, such as the well-known sildenaﬁl (Viagra),
vardenaﬁl (Levitra), and tadalaﬁl (Cialis), have been used to
treat male erectile dysfunction (ED) (43–49). Understanding the
protein structures, particularly the active site structures, and
catalytic mechanism will provide a solid basis for rational
design of novel, more potent inhibitors of PDEs for therapeutic
treatment of a number of human diseases.
PDE families share a similar active site structure. In par-
ticular, a conserved carboxyl-terminal catalytic domain con-
tains a histidine-rich motif [HD(X2)H(X)4N] and two divalent
metal ion-binding sites (3,50,51). A divergent amino-terminal
domain confers isoform-speciﬁc regulatory properties. Xu
et al. (52) ﬁrst reported a three-dimensional (3D) x-ray crystal
structure of the catalytic domain of human phosphodiesterase
4B2B (PDE4). In the reported x-ray crystal structure, the
active site contains a cluster of two divalent metal ions,
denoted byMe1 andMe2.Me1 should be a Zn21 ion based on
the observed geometry of the metal-coordinating ligands, the
anomalous x-ray diffraction behavior, the existing biochem-
ical evidence, and the known high afﬁnity of PDE4 for zinc.
Me2 is most likelyMg21 (53,54), but the possibility ofMe2¼
Mn21 or Zn21 cannot be ruled out (52). According to the 3D
x-ray crystal structure reported by Xu et al. (52), in the PDE4
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active site Asp-392 residue coordinates Me1 through an Od
atom, His-238 and His-274 residues coordinate Me1 through
the nitrogen atoms (denoted by Ne) on the side chain, and four
solvent water molecules coordinate Me2 through the O atoms.
In addition, there are two bridging ligands. One bridging
ligand is clearly Asp-275, whose two oxygen atoms (denoted
by Od) on the side chain respectively coordinate Me1 and
Me2. However, it was uncertain whether the second bridging
ligand (BL2) is a water molecule or a hydroxide ion because
hydrogen atoms cannot be determined by an x-ray diffraction
technique regardless of the resolution of the x-ray crystal
structure. Such a structural problem is also difﬁcult to solve by
using other existing experimental approaches. For example,
biochemical experiments would not be able to directly deter-
mine whether BL2 should be a water molecule or a hydroxide
ion without using any hypothesis. Nuclear magnetic reso-
nance (NMR), in principle, might be a potentially useful ap-
proach to solve such a structural problem, but no NMR study
on such a bridging ligand (water molecule versus hydroxide
ion) has ever been reported as far as we know.
In addition, we note that some interesting model com-
pounds have been synthesized and reported in literature
for mimicking bimetallic active sites of PDE or other simi-
lar metalloenzymes (55). Of particular interest, the dizinc
model compounds synthesized have either a tightly bridged
Zn-O(H)-Zn or a more loosely bridged Zn-(H)O. . .HO(H)-Zn
unit. The more loosely bridged Zn-(H)O. . .HO(H)-Zn unit
might be interesting for understanding the detailed catalytic
process, although the study presented here concerns only the
resting state of the enzymes. As far as the resting state is
concerned, the x-ray crystal structures of PDE reported so far
all demonstrated that BL2 in the PDE active sites should be
either a water molecule or a hydroxide ion.
Xu et al. (52) further considered the possible position of
substrate cAMP in the PDE4 active site to discuss the
catalytic mechanism based on the PDE4 structure in which
Me1 ¼ Zn21 and Me2 ¼ Mg21. They concluded from a
model of cAMP docked in the PDE4 active site that a water
molecule coordinating one or both metal ions could act as the
nucleophile in the catalytic hydrolysis because they consid-
ered the second bridging ligand (BL2) to be a water molecule
(52). Obviously, compared to a water molecule coordinating
to one metal ion, the postulated bridging water molecule
should be a worse nucleophile, whereas a possible bridging
hydroxide ion should be a better nucleophile. For this reason,
if BL2 is a water molecule, the nucleophile is likely a water
molecule coordinating one metal ion (Me2). If BL2 is a
hydroxide ion, the nucleophile is likely the bridging hy-
droxide ion. Thus, it is a key step for determining the
nucleophile in the catalytic hydrolysis and understanding the
catalytic mechanism to identify the structural form of BL2.
The structural form of this critical bridging ligand should
also affect the enzyme binding with substrates or inhibitors.
Our previous ﬁrst-principles quantum mechanical (QM)
calculations (56) on simpliﬁed active site models of PDE4
indicated that a hydroxide ion can bridge the two positively
charged metal ions, whereas a water molecule can coordinate
to only one of the two metal ions. The QM calculations (56)
were performed by using gradient-corrected density func-
tional theory (DFT) with Becke’s three-parameter hybrid
exchange functional and the Lee-Yang-Parr correlation
functional (B3LYP) (57–59) in combination with the 6-
31G* basis set (60,61). The computational results suggest
that BL2 in the active site of the reported x-ray crystal
structure of PDE4 might be a hydroxide ion rather than a
water molecule, to serve as the nucleophile to initialize the
catalytic degradation of the intracellular second messenger.
However, the effects of the protein environment were not
accounted for in the QM calculations. It is unclear whether
the protein environment affects the structural identity of BL2
or not.
Sung et al. (62) reported 3D x-ray crystal structures of the
catalytic domain (residues 537 to 860) of a cGMP-speciﬁc
human PDE5 complexed with three drug molecules, i.e.,
sildenaﬁl (Viagra), tadalaﬁl (Cialis), and vardenaﬁl (Levitra).
Most recently reported x-ray crystal structures of PDE4 and
PDE5 have also demonstrated similar active site structures
(63,64). All of these crystal structures consistently demon-
strate that the active site of PDE5 is located at the center
of the C-terminal helical bundle domain. Summarized in
Table 1 are the geometric parameters from both the ﬁrst (52,
62) and newer (64,65) x-ray crystal structures. The substrate
pocket is ;10 A˚ deep, with a narrow opening and a wide
inner space, giving a total volume of ;330 A˚3. It is com-
posed of four subsites: a metal-binding site (M site), core
pocket (Q pocket), hydrophobic pocket (H pocket), and lid
region (L region). Overall, the M site and Q pocket are
similar to those of PDE4, but the H pocket and the L region
show signiﬁcant structural differences compared to PDE4.
The M site contains both a zinc ion (Me1) and a second metal
ion (Me2, likely Mg21) and is surrounded by helices a6, a8,
a9, a10, and a12 (3). The ﬁrst bridging ligand was clearly
Asp-654. However, the second bridging ligand (BL2) was
described as a water molecule (62–66).
The background summarized above reveals that it is still
unclear whether BL2, a critical bridging ligand, in the active
site of PDE5 and PDE4 should be H2O or HO
. Further, it is
also unknown whether the structural form (H2O or HO
) of
BL2 in the PDE5 active site is the same as that in the PDE4
active site or not and whether the speciﬁc protein environ-
ment can alter the structural form of BL2 or not. Reasonable
answers to these fundamental structural questions are crucial
for understanding the catalytic mechanisms of PDEs, for
studying enzyme–ligand (substrate or inhibitor) binding, and
for future rational design of novel drugs targeting PDEs. For
example, different answers to this question may point to
different possible nucleophiles attacking the phosphorus
center of the substrate (cAMP or cGMP) to initialize the
catalytic reaction. In addition, the structural identity of BL2
should also affect the PDE binding with substrates and
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inhibitors, as different structural forms (neutral H2O or
negatively charged HO) of BL2 would provide different
electrostatic potentials affecting PDE binding with a sub-
strate or inhibitor. Thus, a drug design and discovery effort
based on an incorrect structural identity of BL2 could lead
only to meaningless predictions.
To answer the above crucial structural questions, we have
carried out extensive molecular dynamics (MD) simulations
and hybrid quantum mechanical/molecular mechanical
(QM/MM) calculations, to our knowledge for the ﬁrst time,
on the entire catalytic domains of PDE4 and PDE5. TheseMD
simulations and QM/MM calculations accounting for the spe-
ciﬁc protein environmental effects provide consistent answers
to these structural questions.
COMPUTATIONAL STRATEGY AND METHODS
Although it is unknown whether the second bridging ligand (BL2) in the
active site of PDE4 and PDE5 should be H2O or HO
, the available x-ray
crystal structures (52,62–66) have clearly provided the relative positions of
the heavy atoms. In particular, all of the x-ray crystal structures clearly show
that BL2 bridges the two metal ions in the active site for both PDE4 and
PDE5. Based on these x-ray crystal structures, we wanted to further examine
which structural form (H2O or HO
) of BL2 can bridge the two metal ions in
the active site for each PDE family (PDE4 and PDE5) and, therefore, can
lead to a 3D structure that is consistent with the corresponding x-ray crystal
structures. To solve this structural problem, we performed two sets of MD
simulations and QM/MM calculations for each PDE. The two sets of
modeling studies started from the same x-ray crystal structure for each PDE.
However, BL2 was set to H2O in one set of modeling studies, whereas BL2
was set to HO in the other set of modeling studies. These two sets of
modeling studies allow us to determine which structural form (HO or H2O)
of BL2 leads to a protein structure being consistent with the corresponding
x-ray crystal structure for each PDE. Such a computational strategy can
complement the x-ray diffraction techniques to answer such kinds of
complex questions of protein structure that cannot be answered by the x-ray
diffraction experiment alone.
The standard protonation states at physiological condition (pH ;7.4)
were set to all ionizable residues, and the proton was set on the Ne atom for
all His residues. As seen in Figs. 1–4, His-238 and His-274 of PDE4 and
His-617 and His-653 of PDE5 all coordinate the Zn21 ion through the other
nitrogen atom (denoted by Nh) on the side chain. The Amber7 program suite
(67) was used to perform all the MD simulations in this study. The partial
atomic charges for the nonresidue atoms of hydroxide ion were calculated by
using the restricted electrostatic potential (RESP) ﬁtting protocol imple-
mented in the Antechamber module of the Amber7 program after elec-
trostatic potential (ESP) calculations at ab initio HF/6-31G* level. Each
aforementioned initial structure was neutralized by adding counterions and
was solvated in a rectangular box of TIP3P water molecules with a minimum
solute–wall distance of 10 A˚. Speciﬁcally, the net charge is 19 for the
PDE4 (BL2 ¼ HO) structure, 18 for the PDE4 (BL2 ¼ H2O) structure, 0
for the PDE5 (BL2 ¼ HO) structure, and 11 for the PDE5 (BL2 ¼ H2O)
structure. Hence, 19 Na1 ions were added to neutralize the solvated PDE4
(BL2 ¼ HO) system, 18 Na1 ions were added to neutralize the solvated
PDE4 (BL2 ¼ H2O) system, and one Cl was added to neutralize the sol-
vated PDE5 (BL2 ¼ H2O) system. The total number of atoms in each sol-
vated protein structure for the MD simulations is more than 40,000, although
the total number of atoms of each PDE with the substrate is only ;5000.
The general procedure for carrying out the MD simulations in water is
essentially the same as that used in our previous MD simulations on other
similar protein systems containing a bimetallic active site (68–70). The
nonbonded models were used for the metal ions. The MD simulations in this
study were performed by using the Sander module of the Amber7 program.
The protein–solvent system was optimized before the simulation as follows.
TABLE 1 Some key internuclear distances (A˚) involving the metal ions in the QM/MM-optimized geometries* of PDE4 and PDE5
structures in comparison with the corresponding distances in the x-ray crystal structures
Internuclear distances
in PDE4/5 active site§
PDE4 PDE5
BL2 ¼ OH BL2 ¼ H2O BL2 ¼ OH BL2 ¼ H2O
Me2 ¼
Mg21
Me2 ¼
Zn21
Me2 ¼
Mn21
Me2 ¼
Mg21 Expt.y x-ray
Me2 ¼
Mg21
Me2 ¼
Zn21
Me2 ¼
Mn21
Me2 ¼
Mg21 Expt.z x-ray
Me1-O (HO or H2O) 1.94 (2.05) 1.93 1.93 3.70 1.90 (2.14) 1.98 1.98 1.98 3.58 2.54 (2.05)
Me1-O (Asp-275/654) 2.20 (2.09) 2.63 3.76 2.00 2.20 (2.16) 2.23 2.45 2.27 1.98 2.06 (2.11)
Me1-O (Asp-392/764) 2.08 (2.17) 1.96 1.92 1.91 2.20 (2.08) 2.02 1.98 2.02 1.97 2.07 (2.08)
Me1-N (His-238/617) 2.02 (2.01) 2.01 2.02 1.98 2.00 (2.15) 2.03 2.01 2.02 1.97 2.09 (2.14)
Me1-N (His-274/653) 2.08 (2.05) 2.05 2.04 2.01 2.10 (2.15) 2.07 2.05 2.05 1.99 2.09 (2.14)
Me2-O (HO or H2O) 1.94 (2.05) 1.86 1.95 2.01 2.40 (2.11) 1.96 1.89 2.00 2.00 2.37 (2.07)
Me2-O (Asp-275/654) 2.05 (2.05) 2.07 3.27 2.05 2.40 (2.18) 2.08 1.93 2.13 2.04 2.10 (2.11)
Me2-O (W1) 2.28 (2.27) 3.49 3.61 2.18 2.49 (2.19) 2.21 2.06 2.33 2.29 2.29 (2.11)
Me2-O (W2) 2.18 (2.16) 2.31 2.24 2.14 2.34 (2.15) 2.26 3.70 2.38 2.25 2.39 (2.13)
Me2-O (W3) 2.19 (2.15) 2.21 2.44 2.17 2.57 (2.21) 2.22 4.44 2.46 2.14 2.29 (2.10)
Me2-O (W4) 2.11 (2.11) 2.08 2.16 2.12 2.18 (2.17) 2.06 2.00 2.15 2.09 2.28 (2.12)
*The geometries were fully optimized by performing the QM/MM calculations at the B3LYP/6-31G*:Amber level. The internuclear distances given in
parentheses for PDE4 (BL2 ¼ HO) refer to another PDE4 (BL2 ¼ HO) structure (with Asp-392 residue protonated) obtained from the QM/MM geometry
optimization using the initial structure of PDE4 (BL2 ¼ H2O); during the geometry optimization, a proton was transferred from BL2 (i.e., H2O) to an
Od atom of Asp-392 side chain so that the Asp-392 side chain is protonated (see text for the detailed description).
yExperimental values from the ﬁrst x-ray crystal structure of PDE4 (pdb code 1F0J (52)). The corresponding values in the parentheses are experimental
values from the latest x-ray crystal structure of PDE4 (pdb code 1XOM (64)).
zExperimental values from the ﬁrst x-ray crystal structure of PDE5 (pdb code 1RKP (62)). The corresponding values in the parentheses are experimental
values from the latest x-ray crystal structure of PDE5 (pdb code 1TBF (66)).
§Numbering of the active site residues used here is based on PDE4B2B/PDE5A. W1, W2, W3, and W4 represent the water molecules coordinating the
second metal ion (Me2).
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First, the protein was frozen, and the solvent molecules with counterions
were allowed to move during a 3000-step minimization. Second, all the
atoms were allowed to relax by a 3000-step full minimization. After full
relaxation, the protein was frozen, and the solvent molecules with the
counterions were allowed to move during a 2500-step MD simulation. Then,
with all the atoms in relaxation, the system was slowly heated to 250 K in 20
ps and then to 298.15 K in 80 ps. The production MD simulation at T ¼
298.15 K was kept running until we believed that a stable MD trajectory had
been obtained for each of the simulated structures. The time step used for the
MD simulations was 2 fs. Periodic boundary conditions in the constant
pressure and temperature (NPT) ensemble (i.e., isothermal-isobaric ensem-
ble) at T ¼ 298.15 K with Berendsen temperature coupling (71) and P ¼ 1
atm with isotropic molecule-based scaling (71) were applied. The SHAKE
algorithm (72) was used to ﬁx all covalent bonds containing a hydrogen
atom. The nonbonded pair list was updated every 10 steps. The particle mesh
Ewald (PME) method (73) was used to treat long-range electrostatic
FIGURE 1 Geometry of the PDE4 structure (with Me1 ¼ Zn21, Me2 ¼
Mg21, and BL2 ¼ HO) optimized by the QM/MM calculation at the
B3LYP/6-31G*:Amber level. The high-layer atoms are in the PDE4 active
site represented by the balls in colors other than yellow. The yellow balls
represent the low-layer atoms of the residues coordinating the metal ions.
FIGURE 3 Geometry of the PDE5 structure (with Me1 ¼ Zn21, Me2 ¼
Mg21, and BL2 ¼ HO) optimized by the QM/MM calculation at the
B3LYP/6-31G*:Amber level. The high-layer atoms are represented by the
balls in colors other than yellow. The yellow balls represent the low-layer
atoms of the residues coordinating the metal ions.
FIGURE 4 Geometry of the PDE4 structure (with Me1 ¼ Zn21, Me2 ¼
Mg21, and BL2 ¼ H2O) optimized by the QM/MM calculation at the
B3LYP/6-31G*:Amber level. The high-layer atoms are represented by the
balls in colors other than yellow. The yellow balls represent the low-layer
atoms of the residues coordinating the metal ions.
FIGURE 2 Geometry of the PDE4 structure (with Me1 ¼ Zn21, Me2 ¼
Mg21, and BL2 ¼ H2O) optimized by the QM/MM calculation at the
B3LYP/6-31G*:Amber level. The high-layer atoms are represented by the
balls in colors other than yellow. The yellow balls represent the low-layer
atoms of the residues coordinating the metal ions.
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interactions. A residue-based cutoff of 10 A˚ was utilized for the noncovalent
interactions. The coordinates of the simulated systems were collected every
1 ps during the production MD stages.
The ONIOM approach (74–76) implemented in the Gaussian03 program
(77) was used to fully optimize geometries of the PDE4 and PDE5
structures. Two layers were deﬁned in each of our ONIOM calculations: the
high layer (including the metal ions and atoms from all ligands coordinating
the metal ions; see below for the speciﬁc high-layer atoms depicted as the
balls in Figs. 1–4) was treated quantum mechanically at the B3LYP/6-31G*
level, and the low layer was treated molecular mechanically by using the
Amber force ﬁeld as used in our MD simulations with the Amber7 program.
The low layer included all of the amino acid residues, the two metal ions,
BL2, and all water molecules coordinating the metal ions; the other solvent
water molecules were neglected in the QM/MM calculations. Some missing
force ﬁeld parameters (including the RESP charges for HO and van der
Waals parameters for Zn21 and Mg21) were added before running the
QM/MM calculations with ONIOM approach. The RESP charges used for
HO were calculated at the HF/6-31G* level to be1.206 and 0.206 for the
O and H atoms, respectively. The van der Waals parameters for Zn21 and
Mg21 came from the ‘‘parm99.dat’’ data ﬁle of the Amber force ﬁeld (67);
these parameters were missing in the ‘‘parm96.dat’’ data ﬁle adopted by the
Gaussian03 (77).
The initial PDE4 and PDE5 structures used in the MD simulations and
QM/MM calculations were built from the corresponding x-ray crystal
structures (52,63) deposited in the Protein Data Bank (78) (Protein Data
Bank (pdb) code: 1FOJ for PDE4 and 1RKP for PDE5). All of the MD
simulations and QM/MM calculations started from the same x-ray crystal
structures in terms of the coordinates of the nonhydrogen atoms. The MD
simulations and QM/MM calculations were performed on an HP Superdome
supercomputer (a shared-memory system with a total of 256 processors and
parallel computing) at University of Kentucky Center for Computational
Sciences and on a 34-processor IBM x335 Linux cluster (with parallel
computing) in our own lab.
RESULTS AND DISCUSSION
As mentioned above, in both proteins PDE4 and PDE5, Me1
is known to be Zn21 and Me2 is most likely Mg21. Unless
explicitly stated otherwise, all MD simulations and QM/MM
calculations discussed below were carried out for the protein
structures in which Me1 ¼ Zn21 and Me2 ¼ Mg21.
MD-simulated structures
The trajectory of the MD simulation on the solvated
PDE4(BL2¼HO) system was quickly stabilized after
;200 ps. Thus, the MD simulation was stopped at 800 ps.
It needed a little longer time to obtain a stable MD trajectory
for each of other solvated protein systems. So, the other MD
simulations were stopped at either 2000 ps or 3000 ps.
Depicted in Figs. 5 and 6 are plots of the simulated key
internuclear distances between the metal ions and the oxygen
atom (O) in the examined second bridging ligand (BL2 ¼
HO or H2O) versus the simulation time, along with root
mean-square deviation (RMSD) of the positions of backbone
atoms in the simulated structure from those in the initial struc-
ture. As seen in Figs. 5 and 6, the RMSD values are all
smaller than 2.0 A˚ for all of the MD trajectories, demon-
strating that the backbones of the proteins PDE4 and PDE5
did not dramatically change in going from their crystal
structures to the protein structures in water. Speciﬁcally, the
average RMSD value is 1.30 A˚ for PDE4 (BL2¼HO) over
200–800 ps, 1.88 A˚ for PDE4 (BL2¼H2O) over 1000–2000
ps, 1.55 A˚ for PDE5 (BL2 ¼ HO) over 2000–3000 ps, and
1.73 A˚ for PDE5 (BL2 ¼ H2O) over 1000–2000 ps. The
FIGURE 5 Plots of the key internuclear distances (A˚) versus the sim-
ulation time in the MD-simulated PDE4 structures in water. Zn-O refers to
the distance between the Zn21 ion and the BL2 (the second bridging ligand)
oxygen. Mg-O represents the distance between the Mg21 ion and the BL2
oxygen. RMSD represents the root mean-square deviation (A˚) of the
simulated positions of PDE4 backbone atoms from those in the initial x-ray
crystal structure. BL2 ¼ HO (a) or H2O (b).
FIGURE 6 Plots of the key internuclear distances (A˚) versus the
simulation time in the MD-simulated PDE5 structures. Zn-O refers to the
distance between the Zn21 ion and the BL2 (the second bridging ligand)
oxygen. Mg-O represents the distance between the Mg21 ion and the BL2
oxygen. RMSD represents the root mean-square deviation (A˚) of the
simulated positions of PDE5 backbone atoms from those in the initial
structure. BL2 ¼ HO (a) or H2O (b).
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RMSD values associated with BL2 ¼ H2O are systemati-
cally larger than the RMSD values associated with BL2 ¼
HO, implying that the protein structures with BL2 ¼ HO
might be slightly more stable than the corresponding
structures with BL2 ¼ H2O.
A survey of the simulated distances depicted in Figs. 5 and
6 reveals a remarkable difference between the structures
simulated with BL2 ¼ HO and with BL2 ¼ H2O. When
BL2 was considered to be HO, the simulated average
distances between the BL2 oxygen and two metal ions (Zn21
and Mg21) in both PDE4 and PDE5 are close to ;2.0 A˚,
showing that a hydroxide ion as BL2 coordinated to the two
metal ions simultaneously in the simulated PDE4 and PDE5
structures. When BL2 was regarded as H2O, in the simulated
structures of PDE4 and PDE5, the average distance between
the BL2 oxygen and Mg21 (Me2) is 1.99 A˚ in PDE4 and
2.01 A˚ in PDE5, whereas the average distance between the
BL2 oxygen and Zn21 (Me1) is 3.54 A˚ in PDE4 and 3.45 A˚
in PDE5. The BL2 oxygen coordinated to only the second
metal ion (Me2) and left the ﬁrst metal ion (Me1) during the
MD simulations of the PDE4 and PDE5 structures, when
BL2 was regarded as H2O. So, only the structures simulated
with BL2 ¼ HO are qualitatively consistent with the cor-
responding x-ray crystal structures for both PDE4 and PDE5.
The MD simulations suggest that BL2 should be a hydroxide
ion rather than a water molecule.
The remaining question is whether the MD simulations
based on classical force ﬁeld parameters are or are not reliable
to answer such a complex structural question. Nevertheless,
as discussed below, the results obtained from the MD sim-
ulations are supported by the results obtained from the QM/
MM calculations in which the QM-treated atoms (the high
layer) include the metal ions and all of the atoms coordinating
the metal ions.
Geometries optimized by the QM/MM
calculations on the systems in which
Me1 ¼ Zn21 and Me2 ¼ Mg21
Some important internuclear distances in the QM/MM-
optimized geometries of PDE4 and PDE5 structures are
summarized in Table 1, in comparison with the correspond-
ing experimental data in the x-ray crystal structures. The
optimized protein structures are depicted in Figs. 1–4, where
the high-layer atoms are highlighted by the balls.
As seen in Table 1, the QM/MM-optimized geometries are
qualitatively consistent with the corresponding MD-simu-
lated structures discussed above. For both PDE4 and PDE5,
only a hydroxide ion (considered as BL2) can bridge the two
positively charged metal ions, whereas a water molecule
(considered as BL2) can coordinate to only one metal ion
and left the other metal ion during the geometry optimiza-
tions. Speciﬁcally, when BL2 ¼ H2O, we carefully tested
using different initial geometries in the geometry optimiza-
tions, including starting from the optimized geometries of the
corresponding proteins with BL2 ¼ HO, but an additional
proton was added to the hydroxide oxygen. In turned out that
all of the geometry optimizations using different initial
geometries eventually led to qualitatively the same geome-
tries concerning whether BL2 coordinates one or two metal
ions in the active site. For a special test of the QM/MM
geometry optimization on the proposed PDE4 (BL2 ¼ H2O)
structure, we ﬁrst performed a partial geometry optimization
with two critical internuclear distances ﬁxed at the experi-
mental values in the x-ray crystal structure: one is the
internuclear distance between Zn21 (Me1) and the BL2
oxygen, and the other is that between Mg21 (Me2) and the
BL2 oxygen. However, during such a partial geometry
optimization, a proton in BL2 left the BL2 oxygen and went
to form a covalent bond with the Asp-392 Od atom, which
does not coordinate the metal ions. The partial geometry
optimization was followed by a full geometry optimization.
The ﬁnally optimized O(BL2)–H(BL2) and Od(Asp-392)–
H(BL2) distances are 1.74 and 1.00 A˚, respectively. So, the
partial optimization of the proposed PDE4 (BL2 ¼ H2O)
structure followed by the full optimization actually led to
another PDE4 (BL2 ¼ HO) structure in which the Asp-392
side chain is protonated. The key geometric parameters in
this optimized PDE4 (BL2 ¼ HO) geometry are also
summarized in Table 1 for comparison.
When BL2 ¼ HO, the optimized distances between the
BL2 oxygen and Zn21 (Me1) and between the BL2 oxygen
and Mg21 (Me2) in PDE4 are all ;1.94 A˚, and the cor-
responding distances optimized in PDE5 are 1.98 and 1.96 A˚,
respectively. These QM/MM-optimized distances are rea-
sonably close to the corresponding experimental values in the
x-ray crystal structures, as seen in Table 1.
When BL2 ¼ H2O, the optimized distance between the
BL2 oxygen and Mg21 (Me2) is 2.01 A˚ in PDE4 and 2.00 A˚
in PDE5, whereas the optimized distance between the BL2
oxygen and Zn21 (Me1) is 3.70 A˚ in PDE4 and 3.58 A˚ in
PDE5. The optimized distances between the BL2 oxygen
and Zn21 (Me1) are considerably longer than the experi-
mental values (1.90 to 2.54 A˚) in the x-ray crystal structures.
The protein structures optimized by the QM/MM calcu-
lations are consistent with the MD simulations and conﬁrm
that BL2 in the PDE active site should be HO, rather than
H2O, for both PDE4 and PDE5.
It should be pointed out that the QM/MM-optimized
geometric parameters summarized in Table 1 for PDE4 are
all qualitatively consistent with the corresponding parame-
ters reported in the earlier QM study (56) of the simpliﬁed
PDE4 model system in terms of the coordination of the two
metal ions. However, the speciﬁc internuclear distances
optimized by performing the QM/MM calculations at the
B3LYP:Amber level, accounting for effects of the protein
environment, are signiﬁcantly different from the correspond-
ing distances optimized at the B3LYP/6-31G* level for the
simpliﬁed PDE4 active site model neglecting effects of the
protein environment. For example, the Me1-O(HO) and
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Me2-O(HO) distances optimized at the B3LYP/6-31G*
level for the simpliﬁed PDE4 model system are ;1.95 and
;1.99 A˚, respectively, whereas the corresponding Me1-
O(HO) and Me2-O(HO) distances optimized at the QM/
MM(B3LYP:Amber) level accounting for effects of the pro-
tein environment are all ;1.94 A˚. Thus, for more accurate
determination of the protein structures, effects of the protein
environment should be accounted for. Thus, we performed
the QM/MM geometry optimizations for PDE5 structures, in
addition to the MD simulations, in the computational study
presented here.
Geometries of PDE4 and PDE5 with different
metal ions
All of the above-mentioned MD simulations and QM/MM
calculations were performed for the PDE4 and PDE5
structures in which Me1 ¼ Zn21 and Me2 ¼ Mg21. As
discussed above, Me1 is clearly Zn21, and, therefore, there is
no question concerning the identity of Me1. Me2 is most
likely Mg21, but the possibilities of Me2 ¼ Zn21 or Mn21
cannot be ruled out. We also wanted to know whether the
second bridging ligand (BL2) in the active site of PDE4 and
PDE5 could be H2O or not when Me2 was replaced by Zn
21
or Mn21. So, we also optimize the geometries of the possible
PDE4 and PDE5 structures in which Me1¼ Zn21 and Me2¼
Zn21 or Mn21 by carrying out the QM/MM calculations at
the B3LYP/6-31G*:Amber level. The optimized geometries
of the PDE4 and PDE5 structures (with Me1¼ Zn21, Me2¼
Mg21, and BL2 ¼ HO) were used as the starting structures
(with the necessary replacement of Me2 and BL2) to opti-
mize the geometries of the corresponding PDE4 and PDE5
structures (with Me1 ¼ Zn21, Me2 ¼ Zn21 or Mn21, and
BL2 ¼ HO or H2O).
The QM/MM geometry optimizations with Me1 ¼ Zn21
and Me2 ¼ Zn21 or Mn21 led to protein structures similar to
the corresponding structures optimized with Me2 ¼ Mg21
concerning the binding of BL2 with the metal ions in both
PDE4 and PDE5. Only HO as BL2 can bridge the two
positively charged metal ions. When BL2¼ H2O, during the
geometry optimization process, the BL2 oxygen gradually
left one of the two metal ions and coordinated only to the
other metal ion in the active site no matter whether Me2 ¼
Zn21 or Mn21 (the geometries are not shown). Thus, our
conclusion concerning the identity of BL2 does not change
when Mg21 (as Me2) in the active site is replaced by Zn21 or
Mn21 for both PDE4 and PDE5.
Some key internuclear distances in the optimized geome-
tries of the PDE4 and PDE5 structures (with Me1 ¼ Zn21,
Me2¼Zn21 orMn21, and BL2¼HO) are also summarized
in Table 1 for comparison. As seen in Table 1, all of the
distances in the optimized geometries of the PDE4 structures
(with Me1¼ Zn21, Me2¼ Zn21 or Mn21, and BL2¼HO)
are very close to the corresponding distances in the optimized
geometry (with Me1 ¼ Zn21, Me2 ¼ Mg21, and BL2 ¼
HO), except the distance betweenMe2 and the oxygen atom
of a water molecule (W1). The optimizedMe2-W1 distance is
2.28 A˚ when Me2 ¼Mg21, 3.49 A˚ when Me2 ¼ Zn21, and
3.61 A˚whenMe2¼Mn21. These results indicate thatW1 left
Me2 when it was changed fromMg21 to Zn21 orMn21 in the
PDE4 active site. Apparently, the optimized PDE4 structure
with Me2 ¼ Mg21 is in the best agreement with the x-ray
crystal structures of PDE4, which further supports the as-
sumption of Me2 ¼Mg21 in the PDE4 active site.
Concerning the optimized geometries of the PDE5 struc-
tures with different identities of Me2, as seen in Table 1, the
internuclear distances in the PDE5 structure with Me2 ¼
Zn21 and Mn21 are all very close to the corresponding dis-
tances in the PDE5 structure with Me2 ¼ Mg21, except the
distances between Me2 and the oxygen atoms of water mol-
ecules W2 and W3 in the active site of PDE5 with Me2 ¼
Zn21. The Me2–O(W2) distance optimized at the B3LYP/6-
31G*:Amber level is 2.26 A˚ when Me2 ¼ Mg21, 3.70 A˚
when Me2 ¼ Zn21, and 2.38 A˚ when Me2 ¼ Mn21. The
Me2–O(W3) distance optimized at the B3LYP/6-31G*:Am-
ber level is 2.22 A˚ when Me2 ¼Mg21, 4.44 A˚ when Me2 ¼
Zn21, and 2.46 A˚ when Me2 ¼ Mn21. The optimized
geometries of PDE5 with Me2 ¼ Mg21 and with Me2 ¼
Mn21 are all consistent with the x-ray crystal structures of
PDE5, and, therefore, both Me2 ¼ Mg21 and Me2 ¼ Mn21
are possible in the PDE5 active site.
So, all of the MD and QM/MM results consistently reveal
that for both PDE4 and PDE5, the second bridging ligand in
the active site of the reported x-ray crystal structures should
be a hydroxide ion, rather than a water molecule, no matter
whether the uncertain second metal ion is Mg21, Zn21, or
Mn21. This conclusion provides a valuable structural basis
for future rational design of drugs targeting PDE4 and PDE5.
CONCLUSION
Molecular dynamics (MD) simulations and hybrid quantum
mechanical/molecular mechanical (QM/MM) calculations
on phosphodiesterase (PDE) family 4 (PDE4) structure
including the protein environment resolved by the x-ray
diffraction conﬁrm our previous suggestion, which was
based on QM calculations on a simpliﬁed active site model
neglecting the protein environment, that the second bridging
ligand in the PDE4 active site should be a hydroxide ion
rather than a water molecule, which serves as the nucleophile
to initialize the PDE4-catalyzed hydrolysis of substrate
cAMP. The MD simulations and QM/MM calculations on
PDE5 including the protein environment resolved by the
x-ray diffraction demonstrate, for the ﬁrst time to our
knowledge, that the second bridging ligand in the PDE5
active site should also be a hydroxide ion rather than the
water molecule proposed in recent publications reporting
the x-ray crystal structures of PDE5, which serves as the
nucleophile to initialize the PDE5-catalyzed hydrolysis of
substrate cGMP. These conclusions stand no matter whether
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the uncertain second metal ion is Mg21, Zn21, or Mn21 in
both PDE4 and PDE5 in light of the QM/MM calculations on
the PDE4 and PDE5 structures with different metal ions. All
of the computational results consistently indicate that the
effects of the protein environment do not qualitatively
change the identity of the second bridging ligand, implying
that the second bridging ligand in the active site of other
proteins in the PDE superfamily could also be a hydroxide
ion rather than a water molecule, which serves as the
nucleophile to initialize the PDE-catalyzed hydrolysis of the
intracellular second messenger cAMP or cGMP. These fun-
damental structural insights provide a rational basis for future
structure-based design of drugs targeting proteins in the PDE
superfamily.
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